Department of Radiology, Hyogo Ion Beam Medical Center, 1-2-1 Kouto, Shingu-cho, 679-5165, Tatsuno, Hyogo, Japan,
Strahlenther Onkol. 2014 Feb;190(2):186-91. doi: 10.1007/s00066-013-0489-9. Epub 2013 Dec 22.
To retrospectively analyze treatment outcomes after particle therapy using protons or carbon ions for mucosal melanoma of the head and neck (HNMM) at the Hyogo Ion Beam Medical Center, as well as to compare proton therapy (PT) and carbon ion therapy (CIT).
Data from 62 HNMM patients without metastasis, treated with PT or CIT between October 2003 and April 2011 were analyzed. Median patient age was 70.5 years (range 33-89 years). Of the total patients, 33 (53 %) had received PT and 29 (47 %) had undergone CIT. Protocols for 65 or 70.2 GyE in 26 fractions were used for both ion types.
Median follow-up was 18.0 months (range 5.2-82.7 months). The 1-/2-year overall survival (OS) and local control (LC) rates were 93 %/61 % and 93 %/78 % for all patients, 91 %/44 % and 92 %/71 % for the PT patients and 96 %/62 % and 95 %/59 % for the CIT patients, respectively. No significant differences were observed between PT and CIT. Local recurrence was observed in 8 patients (PT: 5, CIT: 3) and 29 (PT: 18, CIT: 11) experienced distant metastases. Acute reactions were acceptable and all patients completed the planned radiotherapy. Regarding late toxicity, grade 3 or greater events were observed in 5 patients (PT: 3, CIT: 2), but no significant difference was observed between PT and CIT.
Our single-institution retrospective analysis demonstrated that particle therapy for HNMM achieved good LC, but OS was unsatisfactory. There were no significant differences between PT and CIT in terms of either efficacy or toxicity.
回顾性分析兵库离子医疗中心采用质子或碳离子对头颈部黏膜黑色素瘤(HNMM)进行粒子治疗的疗效,并比较质子治疗(PT)和碳离子治疗(CIT)的结果。
分析了 2003 年 10 月至 2011 年 4 月期间,62 例无转移的 HNMM 患者接受 PT 或 CIT 治疗的数据。中位患者年龄为 70.5 岁(范围 33-89 岁)。其中 33 例(53%)接受了 PT,29 例(47%)接受了 CIT。两种离子类型均采用 65 或 70.2GyE 的 26 次分割方案。
中位随访时间为 18.0 个月(范围 5.2-82.7 个月)。所有患者的 1 年和 2 年总生存率(OS)和局部控制率(LC)分别为 93%/61%和 93%/78%,PT 患者分别为 91%/44%和 92%/71%,CIT 患者分别为 96%/62%和 95%/59%。PT 和 CIT 之间无显著差异。8 例患者(PT:5 例,CIT:3 例)出现局部复发,29 例(PT:18 例,CIT:11 例)出现远处转移。急性反应可接受,所有患者均完成了计划的放疗。关于迟发性毒性,5 例患者(PT:3 例,CIT:2 例)出现 3 级或更高级别的事件,但 PT 和 CIT 之间无显著差异。
我们的单中心回顾性分析表明,粒子治疗 HNMM 可获得良好的 LC,但 OS 不理想。PT 和 CIT 在疗效和毒性方面均无显著差异。